BidaskClub cut shares of Catalent, Inc. (NYSE:CTLT) from a buy rating to a hold rating in a research note published on Tuesday morning.
CTLT has been the topic of several other reports. Zacks Investment Research cut shares of Catalent from a buy rating to a hold rating in a report on Friday, November 3rd. Wells Fargo & Company restated an outperform rating and set a $39.00 price target (up from $30.00) on shares of Catalent in a report on Thursday, August 31st. J P Morgan Chase & Co restated a buy rating and set a $40.00 price target on shares of Catalent in a report on Tuesday, August 29th. Needham & Company LLC restated a hold rating on shares of Catalent in a report on Monday, October 23rd. Finally, Piper Jaffray Companies boosted their price target on shares of Catalent from $45.00 to $50.00 and gave the company an overweight rating in a report on Tuesday, November 7th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $42.11.
Catalent (CTLT) traded up $1.14 during midday trading on Tuesday, reaching $38.51. 788,300 shares of the company’s stock traded hands, compared to its average volume of 918,402. Catalent has a 12-month low of $22.94 and a 12-month high of $43.39. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The stock has a market cap of $5,070.00, a PE ratio of 26.14, a price-to-earnings-growth ratio of 2.40 and a beta of 1.49.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. During the same period in the previous year, the company posted $0.16 EPS. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. equities research analysts expect that Catalent will post 1.46 earnings per share for the current fiscal year.
In related news, SVP Christine Dolan sold 1,594 shares of Catalent stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.70% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. lifted its position in Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the last quarter. Stifel Financial Corp lifted its position in Catalent by 0.9% during the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after acquiring an additional 96 shares during the last quarter. Aperio Group LLC lifted its position in Catalent by 0.8% during the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after acquiring an additional 190 shares during the last quarter. Capstone Asset Management Co. lifted its position in Catalent by 2.3% during the 2nd quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after acquiring an additional 230 shares during the last quarter. Finally, People s United Financial Inc. lifted its position in Catalent by 1.9% during the 2nd quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after acquiring an additional 356 shares during the last quarter. 95.65% of the stock is owned by hedge funds and other institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.